UY29981A1 - Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico - Google Patents

Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico

Info

Publication number
UY29981A1
UY29981A1 UY29981A UY29981A UY29981A1 UY 29981 A1 UY29981 A1 UY 29981A1 UY 29981 A UY29981 A UY 29981A UY 29981 A UY29981 A UY 29981A UY 29981 A1 UY29981 A1 UY 29981A1
Authority
UY
Uruguay
Prior art keywords
structure similar
conjugates
dendrímero
obtaining
pharmaceutical interest
Prior art date
Application number
UY29981A
Other languages
English (en)
Inventor
Fernandez Sanchez Eduardo
Paez Meireles Rolando
Saez Martinez Vivian Maria
Castro Odio Fidel Raul
Ramon Hernandez Jose Angel
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of UY29981A1 publication Critical patent/UY29981A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
    • C08G65/325—Polymers modified by chemical after-treatment with inorganic compounds containing nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

Una estructura polimérica semejante a dendrímero con cuatro ramas de monometoxipolietilénglicol. El grupo carboxílico puede ser funcionalizado para la obtención de conjugados de interés farmacéutico. la unión de este polietilénglico semejante a dendrímeros a proteínas terapeúticas mejora la estabilidad in vitro e in vivo de éstas.
UY29981A 2005-11-30 2006-11-30 Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico UY29981A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20050241A CU23556A1 (es) 2005-11-30 2005-11-30 Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico

Publications (1)

Publication Number Publication Date
UY29981A1 true UY29981A1 (es) 2007-06-29

Family

ID=37672068

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29981A UY29981A1 (es) 2005-11-30 2006-11-30 Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico

Country Status (17)

Country Link
US (1) US8703893B2 (es)
EP (1) EP1967212B1 (es)
JP (1) JP5123201B2 (es)
KR (1) KR101134983B1 (es)
CN (2) CN101389354A (es)
AR (1) AR058841A1 (es)
AU (1) AU2006319636B2 (es)
BR (1) BRPI0604313A (es)
CA (1) CA2631335C (es)
CU (1) CU23556A1 (es)
EG (1) EG26619A (es)
MY (1) MY150739A (es)
RU (1) RU2409389C2 (es)
UA (1) UA91575C2 (es)
UY (1) UY29981A1 (es)
WO (1) WO2007062610A2 (es)
ZA (1) ZA200804694B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2636599C (en) * 2006-01-20 2014-07-15 Starpharma Pty Limited Modified macromolecule
US8252834B2 (en) 2008-03-12 2012-08-28 The Regents Of The University Of Michigan Dendrimer conjugates
US8889635B2 (en) * 2008-09-30 2014-11-18 The Regents Of The University Of Michigan Dendrimer conjugates
US9017644B2 (en) 2008-11-07 2015-04-28 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
WO2010075423A2 (en) * 2008-12-23 2010-07-01 The Regents Of The University Of Michigan Dendrimer based modular platforms
US8945508B2 (en) 2009-10-13 2015-02-03 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
US8912323B2 (en) 2009-10-30 2014-12-16 The Regents Of The University Of Michigan Multifunctional small molecules
WO2013085718A1 (en) 2011-12-08 2013-06-13 The Regents Of The University Of Michigan Multifunctional small molecules
US10406233B2 (en) 2011-12-21 2019-09-10 The Regents Of The University Of California Telodendrimers with enhanced drug delivery
US9642916B2 (en) 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
KR102136336B1 (ko) 2013-03-05 2020-07-22 한미약품 주식회사 생리활성 폴리펩타이드 결합체의 고수율 생산을 위한 개선된 제조 방법
EP2786766A1 (en) * 2013-04-05 2014-10-08 Ufpeptides S.r.l. Supramolecular aggregates comprising maleimido cores
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac
CU20140003A7 (es) * 2014-01-08 2015-08-27 Ct De Inmunología Molecular Biofarmacuba Conjugado que comprende eritropoyetina y una estructura polimérica ramificada
LT3183264T (lt) 2014-08-19 2021-01-11 Biogen Ma Inc. Pegilinimo būdas
WO2016201448A2 (en) * 2015-06-11 2016-12-15 Prolong Pharmaceuticals, LLC Pegylated granulocyte colony stimulating factor (gcsf)
WO2017094897A1 (ja) 2015-12-04 2017-06-08 全薬工業株式会社 血中滞留性を改善した抗ｉｌ－１７アプタマー
AU2017205693B2 (en) 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
KR20180100624A (ko) 2016-01-08 2018-09-11 아센디스 파마 그로우쓰 디스오더스 에이/에스 증가된 nep 안정성을 갖는 제어 방출성 cnp 작용제
KR102373744B1 (ko) 2016-01-08 2022-03-15 아센디스 파마 그로우쓰 디스오더스 에이/에스 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제
US10835578B2 (en) * 2016-01-08 2020-11-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
EP3400065A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
CA3007979C (en) 2016-01-08 2023-12-19 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
EP3512569A4 (en) 2016-09-15 2020-09-23 The Regents of The University of California ENHANCED HYBRID TELODENDRIMERS
SG10202111952PA (en) 2016-09-29 2021-12-30 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
CN109134282B (zh) * 2017-06-28 2021-03-16 北京键凯科技股份有限公司 一种树状多缩乙二醇衍生物及其制备方法和应用
WO2019001473A1 (zh) * 2017-06-28 2019-01-03 北京键凯科技股份有限公司 一种树状多缩乙二醇衍生物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
JP5170931B2 (ja) 2000-10-16 2013-03-27 中外製薬株式会社 Ｐｅｇ修飾エリスロポエチン
MXPA04004336A (es) * 2001-11-07 2005-05-16 Nektar Therapeutics Al Corp Polimeros ramificados y sus conjugados.
CN1569892A (zh) * 2004-04-30 2005-01-26 新峰生物科技（上海）有限公司 多臂树杈型聚乙二醇与蛋白质或多肽的结合物及其制备方法
US7144978B2 (en) * 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
CN1176137C (zh) * 2002-01-15 2004-11-17 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
ITMI20020951A1 (it) * 2002-05-06 2003-11-06 Univ Degli Studi Trieste Derivati multifunzionali del polietilenglicole loro preparazione ed impiego
PT2644206T (pt) 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
JP2007501811A (ja) 2003-08-08 2007-02-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。
ES2560657T3 (es) * 2004-01-08 2016-02-22 Ratiopharm Gmbh Glicosilación con unión en O de péptidos G-CSF
EP1768700B1 (en) * 2004-07-16 2010-12-15 Nektar Therapeutics Conjugates comprising gm-csf and a polymer
EP1848461A2 (en) * 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
JP2008530178A (ja) * 2005-02-16 2008-08-07 ノボ ノルディスク アクティーゼルスカブ 構造的に明確に定義された分枝重合体と抱合されたインスリン分泌性薬剤の誘導体

Also Published As

Publication number Publication date
RU2409389C2 (ru) 2011-01-20
BRPI0604313A (pt) 2007-01-30
US8703893B2 (en) 2014-04-22
MY150739A (en) 2014-02-28
EP1967212A2 (en) 2008-09-10
CA2631335C (en) 2013-07-16
US20090082537A1 (en) 2009-03-26
EG26619A (en) 2014-04-08
CN101389354A (zh) 2009-03-18
CA2631335A1 (en) 2007-06-07
KR20080072960A (ko) 2008-08-07
JP2009517414A (ja) 2009-04-30
WO2007062610A2 (es) 2007-06-07
WO2007062610A3 (es) 2007-09-20
UA91575C2 (ru) 2010-08-10
KR101134983B1 (ko) 2012-04-09
AU2006319636B2 (en) 2012-10-18
AR058841A1 (es) 2008-02-27
AU2006319636A1 (en) 2007-06-07
ZA200804694B (en) 2009-03-25
EP1967212B1 (en) 2016-09-21
CU23556A1 (es) 2010-07-20
JP5123201B2 (ja) 2013-01-23
CN104906594B (zh) 2016-12-28
RU2008126209A (ru) 2010-01-10
CN104906594A (zh) 2015-09-16

Similar Documents

Publication Publication Date Title
UY29981A1 (es) Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
MX2020006187A (es) Conjugados polimericos del factor viii.
IT1396918B1 (it) Procedimento per la preparazione di nanopiastrine grafeniche ad elevata disperdibilita' in matrici polimeriche a bassa polarita' e relative composizioni polimeriche
Han et al. A novel synergetic targeting strategy for glioma therapy employing borneol combination with angiopep-2-modified, DOX-loaded PAMAM dendrimer
CY1115354T1 (el) Ενωσεις πεγκυλιωμενης ινσουλινης lispro
CY1119954T1 (el) Ολιγοσακχαριτες που περιλαμβανουν μια ομαδα αμινοοξυ- και συζευγματα αυτων
WO2006108052A3 (en) Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
DK2206736T3 (da) Polyglutamat-aminosyre-konjugater og fremgangsmåder
EA201070657A1 (ru) Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина
WO2006138463A3 (en) Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
CO6450686A2 (es) Compuesto biocompatible y su uso
EP2889043A3 (en) Oligosaccharide-protein conjugates
BR112012016021A8 (pt) Formulações estáveis para liofilização de partículas terapêuticas
WO2011015634A3 (en) Controlled release formulations of lipocalin muteins
EP2537533A3 (en) Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation
AR071334A1 (es) Gel de quitosano para aplicaciones dermatologicas, proceso de obtencion y uso del mismo
WO2011143201A3 (en) Ratiometric combinatorial drug delivery
EA201290941A1 (ru) КОНЪЮГИРОВАННЫЙ ФАКТОР СВЕРТЫВАНИЯ КРОВИ VIIa
ATE540996T1 (de) Polymerbasierter serumalbumin-ersatzstoff
WO2009030065A8 (zh) 聚乙二醇修饰的干扰素α2a及其制备方法和应用
WO2010057014A3 (en) Capturing and delivering molecules in a mammal
CA2836069C (en) Polyethylene glycol derivatives of palmitoylethanolamide and analogous acylethanolamides
CL2010001049A1 (es) Composicion que comprende moleculas de factor estimulante de colonias de granulocitos que incluyen una molecula de polietilenglicol unida covalentemente al residuo de lisina mas cercano al extremo n-terminal; formulacion farmaceutica que la comprende; y proceso de preparacion del conjugado.
BRPI0917819B8 (pt) compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado

Legal Events

Date Code Title Description
105 Application deemed to be withdrawn (no grant fee paid)

Effective date: 20200904